True Anaphylaxis with IV Iron is Exceedingly Rare
True anaphylaxis from intravenous iron occurs in fewer than 1 in 200,000 administrations 1. This represents an extraordinarily low risk that should not deter appropriate use of IV iron therapy.
Quantifying the Risk
The most recent expert consensus guidelines from 2024 explicitly state that anaphylaxis due to IV iron is "exceedingly rare, occurring with <1:200,000 administrations" 1. This translates to approximately 0.0005% or 0.5 per 100,000 administrations.
Comparative Data from Large Studies
When examining actual reported cases across different populations:
Medicare population (2013-2018): The adjusted incidence rates ranged from 0.8 to 9.8 cases per 10,000 first administrations depending on the specific iron formulation 2. Iron dextran had the highest rate at 9.8 per 10,000, while ferric carboxymaltose had the lowest at 0.8 per 10,000.
Earlier Medicare data (2003-2013): Identified 274 anaphylaxis cases at first exposure among 688,183 IV iron recipients, with an overall risk of 68 per 100,000 for iron dextran and 24 per 100,000 for all non-dextran products combined 3.
European multinational study (1999-2017): Found only 13-16 anaphylaxis cases among 304,210 patients receiving first IV iron treatment, yielding an incidence of 0.4-0.5 per 10,000 first treatments 4.
IBD patients (2010-2014): Among 37,168 IV iron infusions in 6,151 IBD patients, there were only 0.24 anaphylactic shock events per 1,000 infusions 5.
Critical Distinction: CARPA vs. True Anaphylaxis
The vast majority of infusion reactions are NOT true anaphylaxis but rather complement-activated related pseudo-allergy (CARPA), also known as Fishbane reactions 1. These are physiologically different from IgE-mediated anaphylactic reactions and are managed differently. This distinction is crucial because many reported "allergic reactions" to IV iron are actually CARPA reactions that do not represent true immunologic anaphylaxis.
Formulation-Specific Risk Stratification
The risk varies significantly by formulation:
- Highest risk: Iron dextran (particularly older high-molecular-weight formulations, now withdrawn)
- Intermediate risk: Ferumoxytol (3.4-fold higher than iron sucrose) 2
- Lowest risk: Iron sucrose and ferric carboxymaltose 2
Low-molecular-weight iron dextran maintains an 8-fold higher risk compared to iron sucrose even after high-molecular-weight formulations were removed from the market 2.
Clinical Context
The 2024 expert consensus emphasizes that the "folklore of danger" associated with IV iron is unwarranted 1. The actual risk of true anaphylaxis is lower than many commonly used medications. For perspective, the study found 1.2 anaphylaxis events per 10,000 penicillin treatments 4, which is higher than most IV iron formulations.
No fatal anaphylactic reactions were reported in the dialysis population study of over 1 million iron dextran doses 6, though 7 reactions required resuscitative agents (0.035% incidence).